The Capital Partnership

The Capital Partnership is an independent asset manager established in 1998, based in London, with additional offices in Dubai. It provides a diverse range of asset management and wealth preservation services to institutional and private investors, including families and large institutions in the EMEA region. Initially created to serve the sophisticated investment needs of the founding partners' families, the firm has successfully expanded its offerings to address the asset management requirements of various clients. The Capital Partnership employs a multi-strategy approach, investing in both public and private markets. The group's ultimate holding company is incorporated in the Dubai International Financial Centre, while its UK operating subsidiary is authorized and regulated by the Financial Conduct Authority. Through its expertise, The Capital Partnership assists clients in navigating the complexities of asset growth and preservation.

Gautam Kainth

Managing Director

17 past transactions

Tioga Cardiovascular

Series C in 2023
Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach.

Adona Medical

Series B in 2022
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options and enable providers to improve care for heart failure patients.

Supira Medical

Series C in 2022
Supira Medical, Inc. develops a percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. Its solution is a high-flow percutaneous pVAD for high risk PCI and cardiogenic shock for patients requiring temporary mechanical support during coronary interventions. The company’s solution is placed to provide temporary mechanical support, assisting the native pumping action of the heart and enabling patients to undergo necessary interventional procedures. Supira Medical, Inc. was formerly known as Lumenblation Medical, Inc. and changed its name to Supira Medical, Inc. in March 2016. The company was incorporated in 2012 and is based in Campbell, California.

Akura Medical

Series A in 2022
Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use, single-pass procedure that efficiently removes blood clots.

Tioga Cardiovascular

Series B in 2021
Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach.

Myra Vision

Series A in 2021
Myra Vision specializes in developing innovative surgical techniques aimed at enhancing treatment options for patients suffering from moderate to severe glaucoma. The company has created a unique treatment that significantly reduces intraocular pressure (IOP) while minimizing the risk of hypotony, thereby offering physicians a valuable platform for improving patient outcomes. Myra Vision is a privately held portfolio company of Shifamed LLC and is actively advancing its pioneering treatment through recent funding efforts.

Myra Vision

Series A in 2021
Myra Vision specializes in developing innovative surgical techniques aimed at enhancing treatment options for patients suffering from moderate to severe glaucoma. The company has created a unique treatment that significantly reduces intraocular pressure (IOP) while minimizing the risk of hypotony, thereby offering physicians a valuable platform for improving patient outcomes. Myra Vision is a privately held portfolio company of Shifamed LLC and is actively advancing its pioneering treatment through recent funding efforts.

Supira Medical

Series B in 2020
Supira Medical, Inc. develops a percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. Its solution is a high-flow percutaneous pVAD for high risk PCI and cardiogenic shock for patients requiring temporary mechanical support during coronary interventions. The company’s solution is placed to provide temporary mechanical support, assisting the native pumping action of the heart and enabling patients to undergo necessary interventional procedures. Supira Medical, Inc. was formerly known as Lumenblation Medical, Inc. and changed its name to Supira Medical, Inc. in March 2016. The company was incorporated in 2012 and is based in Campbell, California.

CloudCath

Series A in 2020
CloudCath is a company that specializes in developing a remote monitoring platform for peritoneal dialysis patients. Their innovative system utilizes sensor-enabled technology to provide continuous monitoring, allowing for early detection of complications associated with catheter-based treatments. By leveraging Internet of Things (IoT) capabilities, CloudCath's platform enables healthcare providers to remotely oversee patients during their home treatment, significantly reducing the frequency of in-person visits. This approach not only enhances patient safety but also improves the overall management of care for individuals undergoing peritoneal dialysis, ultimately promoting better health outcomes.

Atia Vision

Series D in 2019
Atia Vision, Inc. operates as a medical device company. It develops modular presbyopia correcting intraocular lens to address the needs in intraocular lens replacement market. Atia Vision, Inc. was incorporated in 2012 and is based in Campbell, California.

Tioga Cardiovascular

Series A in 2019
Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach.

NuVera Medical

Seed Round in 2019
NuVera Medical, Inc. operates an imaging platform for cardiovascular procedures. The product uses 4D ultrasound technology to process the images. The product can be used by healthcare specialists for Intracardiac Echocardiography. NuVera Medical, Inc. was founded in 2016 and is based in Campbell, California.

Atia Vision

Series C in 2018
Atia Vision, Inc. operates as a medical device company. It develops modular presbyopia correcting intraocular lens to address the needs in intraocular lens replacement market. Atia Vision, Inc. was incorporated in 2012 and is based in Campbell, California.

Supira Medical

Series A in 2018
Supira Medical, Inc. develops a percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. Its solution is a high-flow percutaneous pVAD for high risk PCI and cardiogenic shock for patients requiring temporary mechanical support during coronary interventions. The company’s solution is placed to provide temporary mechanical support, assisting the native pumping action of the heart and enabling patients to undergo necessary interventional procedures. Supira Medical, Inc. was formerly known as Lumenblation Medical, Inc. and changed its name to Supira Medical, Inc. in March 2016. The company was incorporated in 2012 and is based in Campbell, California.

NuVera Medical

Series A in 2017
NuVera Medical, Inc. operates an imaging platform for cardiovascular procedures. The product uses 4D ultrasound technology to process the images. The product can be used by healthcare specialists for Intracardiac Echocardiography. NuVera Medical, Inc. was founded in 2016 and is based in Campbell, California.

Cerestra

Acquisition in 2016
Cerestra is a private equity firm focused on investing in socially relevant and business critical real estate assets.

Northgate Mexico

Acquisition in 2016
Northgate Mexico, established in 2014, is a fund of funds managed by Northgate Capital, which is based in Mexico City. This fund focuses on investments in North America, specifically targeting the software and technology, media, and telecommunications (TMT) sectors. As part of Northgate Capital, which was founded in 2000 and has investment offices in San Francisco and London, Northgate Mexico benefits from the firm's extensive experience in venture capital and private equity. Northgate Capital, managing approximately $4.8 billion in assets, employs a team of over 50 investment and finance professionals across its global locations, positioning Northgate Mexico as a key player in the venture capital landscape within its targeted sectors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.